title: Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B.
abstract: BACKGROUND
  The quantitation of serum HBeAg is not commonly used to monitor viral response to therapy in chronic hepatitis B.
  
  
  METHODS
  In this study, 21 patients receiving varying therapies were followed and their viral response monitored by concomitant viral load and HBeAg quantitation in order to study the meaning and the kinetics of both parameters.
  
  
  RESULTS
  It was possible to distinguish between three different patterns of viral response. The first was characterized by a simultaneous decrease in serum HBV DNA and HBeAg. The second pattern was characterized by a decrease in serum HBeAg but persistent detection of HBV DNA. The third pattern was characterized by undetectable HBV DNA with persistent HBeAg positivity, which points to a non-response (Pattern III-B) except when HBeAg levels showed a slow but steady drop, characterizing a 'slow responder' patient (Pattern III-A).
  
  
  CONCLUSIONS
  The first pattern is compatible with a viral response. A long-term HBeAg seropositivity with a slow and persistent decrease (Pattern III-A) is also compatible with a viral response and calls for a prolongation of anti-viral treatment.
authors.affiliation: Department of Gastroenterology, School of Medicine, University of São Paulo. lucadasi@bol.com.br
authors.forename: Luiz Caetano
authors.initials: LC
authors.lastname: da Silva
authors.forename: Maria Luiza da
authors.initials: ML
authors.lastname: Nova
authors.forename: Suzane Kioko
authors.initials: SK
authors.lastname: Ono-Nita
authors.forename: João Renato Rebello
authors.initials: JR
authors.lastname: Pinho
authors.forename: Roberta
authors.initials: R
authors.lastname: Sitnik
authors.forename: Vera Aparecida dos
authors.initials: VA
authors.lastname: Santos
authors.forename: Flair José
authors.initials: FJ
authors.lastname: Carrilho
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D004279:DNA, Viral / Q000097:blood*; D024882:Drug Resistance, Viral; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000097:blood* / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D019562:Viral Load; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens